Plasmablast-like lymphoma cells as a distinct subpopulation confers multidrug resistance in PCNSL

Feng Liang; Xiaotao Zhang; An Ping; Yichen Gu; Ziyang Jin; Huaming Li; Lingxiao Lu; Fan Yang; Junjie Wang; Jianan Lu; Feng Zhou; Jinfang Xu; Jingsen Chen; Junming Zhu; Fengqiang Liu; Jianmin Zhang; Ligen Shi

doi:10.1093/neuonc/noaf154

Plasmablast-like lymphoma cells as a distinct subpopulation confers multidrug resistance in PCNSL

Neuro Oncol. 2025 Jun 21:noaf154. doi: 10.1093/neuonc/noaf154. Online ahead of print.

Authors

Feng Liang^{1

2}, Xiaotao Zhang³, An Ping^{1

4}, Yichen Gu^{1

4}, Ziyang Jin^{1

4}, Huaming Li^{1

4}, Lingxiao Lu^{1

4}, Fan Yang^{1

4}, Junjie Wang^{1

4}, Jianan Lu^{1

4}, Feng Zhou^{1

4}, Jinfang Xu^{1

4}, Jingsen Chen^{1

4}, Junming Zhu^{1

4}, Fengqiang Liu^{1

4}, Jianmin Zhang^{1

5

6

4}, Ligen Shi^{1

4}

Affiliations

¹ Department of Neurosurgery, Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
² Department of Orthopedics, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310058, China.
³ Department of breast surgery, Zhejiang Cancer Hospital, Hangzhou Institute of Medicine (HIM), Chinese Academy of Sciences, Hangzhou, Zhejiang 310022, China.
⁴ Clinical Research Center for Neurological Diseases of Zhejiang Province, Hangzhou, China.
⁵ Brain Research Institute, Zhejiang University, Hangzhou, Zhejiang, China.
⁶ Collaborative Innovation Center for Brain Science, Zhejiang University, Hangzhou, Zhejiang, China.

PMID: 40580931
DOI: 10.1093/neuonc/noaf154

Abstract

Background: Primary central nervous system lymphoma (PCNSL) is a highly aggressive subtype of non-Hodgkin lymphoma that is confined to the central nervous system. PCNSL is associated with a poor 5-year survival rate of 30-40%, partly due to a high recurrence rate of 60%. A comprehensive understanding of the molecular signatures and mechanisms underlying drug resistance in PCNSL is crucial, as it has significant implications for therapeutic strategies.

Methods: A cohort of 56 newly diagnosed PCNSL patients was generated. The tumor specimens were obtained by biopsy. A combined approach, including single-cell transcriptomics and B-cell receptor sequencing, transcriptome-informed multiplex immunohistochemistry, and ex-vivo drug response assays, was applied to reveal the transcriptional and immune microenvironment landscape of PCNSL.

Results: We identify four main B cell subtypes, each characterized by distinct transcriptomic profiles, from malignant B cells in PCNSL. Among these subtypes, plasmablast-like lymphoma cells (PBLCs), characterized by upregulated genes typically associated with plasma cell differentiation, comprise 1.3%-8.1% of malignant B cells and correlate with poor prognosis in PCNSL. PBLCs exhibit reduced expression of CD20, Bruton tyrosine kinase, and FAS, resulting in drug resistance and immune evasion. In addition, PBLCs elevate the expression of critical transcription factors, including XBP1 and PRDM1, to maintain their phenotype. Clinical drugs, such as Lenalidomide, demonstrate potential cytotoxic effects on PBLCs.

Conclusions: These findings highlight PBLCs as a distinct subtype of malignant B cells that plays a critical role in the multidrug resistance of PCNSL and reveal the molecular signature of PBLCs that can be targeted for therapy.

Keywords: Intratumoral heterogeneity; Primary central nervous system lymphoma; multidrug resistance; single-cell RNA sequencing.

© The Author(s) 2025. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.